

# Jo Caers

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3915996/publications.pdf>

Version: 2024-02-01

73  
papers

6,269  
citations

218592

26  
h-index

106281

65  
g-index

74  
all docs

74  
docs citations

74  
times ranked

7941  
citing authors

#	ARTICLE	IF	CITATIONS
1	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, e538-e548.	5.1	3,343
2	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , 2016, 127, 2955-2962.	0.6	686
3	Galectin expression in cancer diagnosis and prognosis: A systematic review. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 235-247.	3.3	188
4	Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. <i>Journal of Hematology and Oncology</i> , 2018, 11, 10.	6.9	181
5	Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports. <i>Supportive Care in Cancer</i> , 2005, 13, 325-331.	1.0	162
6	Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. <i>Blood Cancer Journal</i> , 2018, 8, 105.	2.8	113
7	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. <i>Haematologica</i> , 2018, 103, 197-211.	1.7	110
8	MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. <i>Journal of Hematology and Oncology</i> , 2020, 13, 173.	6.9	91
9	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. <i>Haematologica</i> , 2018, 103, 1772-1784.	1.7	86
10	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. <i>American Journal of Hematology</i> , 2016, 91, 575-580.	2.0	83
11	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). <i>Leukemia</i> , 2018, 32, 1697-1712.	3.3	83
12	Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma. <i>Oncotarget</i> , 2016, 7, 37931-37943.	0.8	78
13	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	1.2	67
14	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. <i>Blood Cancer Journal</i> , 2021, 11, 192.	2.8	62
15	The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma. <i>Haematologica</i> , 2014, 99, 629-637.	1.7	61
16	A Novel Mouse Model for Multiple Myeloma (MOPC315.BM) That Allows Noninvasive Spatiotemporal Detection of Osteolytic Disease. <i>PLoS ONE</i> , 2012, 7, e51892.	1.1	61
17	Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. <i>Frontiers in Immunology</i> , 2020, 11, 762.	2.2	57
18	Extramedullary disease in multiple myeloma: a systematic literature review. <i>Blood Cancer Journal</i> , 2022, 12, 45.	2.8	57

#	ARTICLE	IF	CITATIONS
19	Multiple myeloma – an update on diagnosis and treatment. <i>European Journal of Haematology</i> , 2008, 81, 329-343.	1.1	46
20	Immunomodulatory Effects of the <i>Agaricus blazei</i> Murrill-Based Mushroom Extract AndoSan in Patients with Multiple Myeloma Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation: A Randomized, Double Blinded Clinical Study. <i>BioMed Research International</i> , 2015, 2015, 1-11.	0.9	44
21	Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 11.	2.2	42
22	The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model. <i>British Journal of Haematology</i> , 2005, 132, 051220022257013.	1.2	37
23	Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease. <i>Journal of Hematology and Oncology</i> , 2016, 9, 53.	6.9	33
24	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. <i>Leukemia and Lymphoma</i> , 2016, 57, 2071-2076.	0.6	30
25	The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. <i>Oncologist</i> , 2016, 21, 333-342.	1.9	28
26	Enteroviral meningoencephalitis as complication of Rituximab therapy in a patient treated for diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2010, 150, 379-381.	1.2	27
27	Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment. <i>Bulletin Du Cancer</i> , 2008, 95, 301-13.	0.6	27
28	Biological aspects of angiogenesis in multiple myeloma. <i>International Journal of Hematology</i> , 2011, 94, 505-518.	0.7	26
29	Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma. <i>Haematologica</i> , 2018, 103, 325-335.	1.7	23
30	Thymosin $\alpha$ 4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma. <i>Haematologica</i> , 2010, 95, 163-167.	1.7	22
31	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. <i>Haematologica</i> , 2021, 106, 2799-2812.	1.7	22
32	SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma. <i>Oncotarget</i> , 2016, 7, 30712-30729.	0.8	19
33	A novel mutation in the CLUB sequence of matriptase-2 ( <i>TMPRSS6</i> ) is implicated in iron-resistant iron deficiency anaemia (IRIDA). <i>British Journal of Haematology</i> , 2013, 160, 564-565.	1.2	17
34	Mithramycin Exerts an Anti-Myeloma Effect and Displays Anti-Angiogenic Effects through Up-Regulation of Anti-Angiogenic Factors. <i>PLoS ONE</i> , 2013, 8, e62818.	1.1	17
35	Molecular mechanisms, current management and next generation therapy in myeloma bone disease. <i>Leukemia and Lymphoma</i> , 2018, 59, 14-28.	0.6	17
36	Itacitinib prevents xenogeneic GVHD in humanized mice. <i>Bone Marrow Transplantation</i> , 2021, 56, 2672-2681.	1.3	16

#	ARTICLE	IF	CITATIONS
37	Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. <i>Blood</i> , 2022, 139, 2747-2757.	0.6	16
38	The anti-mitotic agents PTC028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of <i>BMI-1</i> as an essential tumour gene. <i>British Journal of Haematology</i> , 2020, 190, 877-890.	1.2	15
39	Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease. <i>Haematologica</i> , 2018, 103, 1359-1368.	1.7	14
40	The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. <i>Leukemia</i> , 2020, 34, 2451-2459.	3.3	14
41	A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 183.	6.9	12
42	Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians. <i>Annals of Medicine</i> , 2013, 45, 413-422.	1.5	11
43	Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in Osteoclasts. <i>Cancers</i> , 2019, 11, 261.	1.7	11
44	Mass cytometry in POEMS (polyneuropathy, organomegaly, endocrinopathy, M $\alpha$ C protein, skin changes) syndrome: looking for a needle in a haystack. <i>British Journal of Haematology</i> , 2020, 190, 16-17.	1.2	11
45	The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. <i>Journal of Clinical Epidemiology</i> , 2021, 137, 31-44.	2.4	11
46	Establishment of a Murine Graft-versus-Myeloma Model Using Allogeneic Stem Cell Transplantation. <i>PLoS ONE</i> , 2014, 9, e113764.	1.1	11
47	Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents?. <i>Haematologica</i> , 2016, 101, 1276-1278.	1.7	10
48	Thymosin $\beta$ 4 in multiple myeloma: friend or foe. <i>Annals of the New York Academy of Sciences</i> , 2010, 1194, 125-129.	1.8	8
49	Dual-tracer PET/CT scan after injection of combined [ $^{18}$ F]NaF and [ $^{18}$ F]FDG outperforms MRI in the detection of myeloma lesions. <i>Hematological Oncology</i> , 2019, 37, 193-201.	0.8	7
50	Of mice and men: disease models of multiple myeloma. <i>Drug Discovery Today: Disease Models</i> , 2004, 1, 373-380.	1.2	6
51	Altered chondrocyte differentiation, matrix mineralization and MEK-Erk1/2 signaling in an INPPL1 catalytic knock-out mouse model of opsismodysplasia. <i>Advances in Biological Regulation</i> , 2020, 76, 100651.	1.4	6
52	Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma. <i>Cancers</i> , 2021, 13, 3072.	1.7	5
53	Radiotheranostic Agents in Hematological Malignancies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
54	The Effects of Forodesine in Murine and Human Multiple Myeloma Cells. <i>Advances in Hematology</i> , 2010, 2010, 1-8.	0.6	4

#	ARTICLE	IF	CITATIONS
55	Panhypopituitarism and diabetes insipidus in a patient with primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 2515-2516.	0.6	4
56	A First Report on [ <sup>18</sup> F]FPRGD <sup>2</sup> PET/CT Imaging in Multiple Myeloma. <i>Contrast Media and Molecular Imaging</i> , 2017, 2017, 1-7.	0.4	4
57	Acute interstitial nephritis associated with salmonellosis. <i>European Journal of Internal Medicine</i> , 2006, 17, 217-219.	1.0	3
58	Diffuse xanthomatosis as a presenting feature of multiple myeloma. <i>European Journal of Haematology</i> , 2010, 84, 460-461.	1.1	3
59	Haematological and molecular responses in refractory anaemia with ring sideroblasts and thrombocytosis treated with lenalidomide. <i>European Journal of Haematology</i> , 2014, 92, 179-180.	1.1	3
60	Exosomes Play a Key Role in Multiple Myeloma Bone Disease and Tumor Development. <i>Blood</i> , 2018, 132, 4484-4484.	0.6	3
61	Impact of the immunomodulating peptide thymosin alpha 1 on multiple myeloma and immune recovery after hematopoietic stem cell transplantation. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 989-998.	2.0	2
62	Genomic studies of multiple myeloma reveal an association between X chromosome alterations and genomic profile complexity. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 18-27.	1.5	2
63	High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. <i>International Journal of Hematology</i> , 2020, 112, 141-146.	0.7	2
64	Maternal Embryonic Leucine Zipper Kinase (MELK) Drives a High-Risk Gene Network and Represents an Attractive Novel Drug Target in Multiple Myeloma. <i>Blood</i> , 2016, 128, 309-309.	0.6	2
65	Bone mass of the calvarium. <i>Skeletal Radiology</i> , 2013, 42, 1157-1159.	1.2	1
66	Recommendations on the management of multiple myeloma in 2020. <i>Acta Clinica Belgica</i> , 2020, , 1-17.	0.5	1
67	Ac-SDKP: Linking cardiac remodeling to hematological malignancies. <i>Leukemia and Lymphoma</i> , 2006, 47, 1732-1733.	0.6	0
68	Bone mass of the calvarium. <i>Skeletal Radiology</i> , 2013, 42, 1185-1187.	1.2	0
69	Exome copy number variation detection: Use of a pool of unrelated healthy tissue as reference sample. <i>Genetic Epidemiology</i> , 2017, 41, 35-40.	0.6	0
70	The Road to a Cure: Emerging Treatments for Multiple Myeloma. <i>Cancers</i> , 2020, 12, 3593.	1.7	0
71	Bone Marrow Adipocytes Influence Multiple Myeloma Development by Secretion of Different Growth Factors and Chemokines.. <i>Blood</i> , 2006, 108, 5030-5030.	0.6	0
72	Decreased Thymosin Beta 4 Expression Results in Poor Prognosis and Decreased Survival in Multiple Myeloma.. <i>Blood</i> , 2008, 112, 1703-1703.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Serological response to SARS-CoV-2 mRNA-containing lipid nanoparticle vaccine in patients with multiple myeloma: A negative impact of CD38 <sup>+</sup> regulatory T cells?. British Journal of Haematology, 2022, , .	1.2	0